KPTI Karyopharm Therapeutics
- 0.700
- -0.024-3.31%
- 0.707
- +0.007+1.00%
Karyopharm Therapeutics News
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $5
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7
Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating
Karyopharm Therapeutics Analyst Ratings
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7
Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $4
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties
Karyopharm Therapeutics (KPTI) Gets a Buy From RBC Capital
Buy Rating Affirmed for Karyopharm Therapeutics Amid Strong Q2 Performance and Positive Xpovio Sales Outlook
Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5
Karyopharm Therapeutics Analyst Ratings
Karyopharm Therapeutics Analyst Ratings
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
No Data